Author

B. Corleis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Research Focus:drug response / drug discovery· 3 Organism:mouse· 3 Assay:flow cytometry· 1 Organism:human· 1 Organism:rat· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

A. Dorhoi· 3 shared C. Fricke· 3 shared D. Hoffmann· 3 shared L. Ulrich· 3 shared M. Beer· 3 shared N. J. Halwe· 3 shared N. Roth· 3 shared S. Rauch· 3 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. Dorhoi

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Assessment of Immunogenicity and Efficacy of CV0501 mRNA-based Omicron COVID-19 Vaccination in Small Animal Models

N. Roth, J. Gergen, K. Kovacikova, S. Mueller, L. Ulrich, J. Schoen, N. J. Halwe, C. Fricke, B. Corleis, A. Dorhoi, D. Hoffmann, M. Beer, D. Maione, B. W. Petsch, S. Rauch

This paper evaluates the immunogenicity and efficacy of a bivalent mRNA vaccine CV0501 against Omicron subvariants in animal models, showing robust neutralizing antibodies and reduced viral loads.

bioRxiv · Jan 4, 2023Immunology

Tobacco smoke exposure results in recruitment of inflammatory airspace monocytes and accelerated growth of Mycobacterium tuberculosis

B. Corleis, C. N. Tzouanas, M. H. Wadsworth, J. L. Cho, A. H. Linder, A. E. Schiff, A. K. Dickey, B. D. Medoff, A. K. Shalek, D. S. Kwon

Tobacco smoke exposure recruits inflammatory monocytes to the lungs, which support faster Mycobacterium tuberculosis growth.

bioRxiv · Dec 21, 2022 · PreprintImmunology

Low-dose bivalent mRNA vaccine is highly effective against different SARS-CoV-2 variants in a transgenic mouse model

B. Corleis, D. Hoffmann, S. Rauch, C. Fricke, N. Roth, J. Gergen, K. Kovacikova, K. Schlottau, N. J. Halwe, L. Ulrich, J. Schön, K. Wernike, M. Widera, S. Ciesek, S. O. Mueller, , A. Dorhoi

This study shows a low-dose bivalent mRNA vaccine targeting multiple SARS-CoV-2 variants provides strong protection in mice and rats, with comparable antibody levels and reduced viral replication.

bioRxiv · Apr 20, 2022 · PreprintImmunology

CVnCoV protects human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2

D. Hoffmann, B. Corleis, S. Rauch, N. Roth, J. Muehe, N. J. Halwe, L. Ulrich, C. Fricke, J. Schoen, A. Kraft, A. Breithaupt, K. Wernike, A. Michelitsch, F. Sick, C. Wylezich, , M. Beer

This study evaluates the efficacy of the CVnCoV mRNA vaccine against ancestral and emerging SARS-CoV-2 variants in a human ACE2 transgenic mouse model, showing complete protection against B.1.351.

bioRxiv · Mar 22, 2021Microbiology